Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Sep
25
2023
Bonding Requirements Complicate TTB Permit Filing Norris McLaughlin P.A.
Apr
24
2020
Investors: SEC Warns to Be Aware of Uptick of Fraud in the Cannabis Industry Norris McLaughlin P.A.
May
21
2020
Governor Wolf Signs Bill to Allow Mixed Drinks To-Go for Restaurant and Hotel Licensees Norris McLaughlin P.A.
Jan
11
2024
Hopping Towards Change: New Jersey Proposes A Crafty New Solution to the Special Ruling Norris McLaughlin P.A.
Jul
16
2020
“I Thought Groundhog Day Was in February?” Pennsylvania Governor Rewinds Clock Restricting the Operations of Bars and Restaurants to Mitigate the Spread of the Coronavirus Norris McLaughlin P.A.
Mar
24
2010
Personalized Medicine and Patentability: Important Considerations After Healthcare Reform Sterne, Kessler, Goldstein & Fox P.L.L.C.
Dec
16
2014
USPTO Issues New Subject Matter Eligibility Examination Interim Guidelines – Nature-Based Product Guidance Sterne, Kessler, Goldstein & Fox P.L.L.C.
Mar
23
2015
One More Hurdle Cleared – Amgen’s Preliminary Injunction Motion for Filgrastim is Denied Sterne, Kessler, Goldstein & Fox P.L.L.C.
Aug
15
2017
Patent Term Extension Considerations for BioPharma Patents Sterne, Kessler, Goldstein & Fox P.L.L.C.
Apr
12
2010
New U.S. Law Establishes Long Awaited Abbreviated Approval Pathway for Biosimilars Sterne, Kessler, Goldstein & Fox P.L.L.C.
Jan
22
2015
Can Digital Healthcare Innovation Be Patented? Eligibility of Digital Healthcare Technologies Under the New USPTO Eligibility Guidelines Sterne, Kessler, Goldstein & Fox P.L.L.C.
Apr
17
2015
BIO Files Brief in Support of Mandatory Notice Requirement in the BPCIA Sterne, Kessler, Goldstein & Fox P.L.L.C.
Dec
30
2015
TTAB Finds MEAT CANDY to be Too Sweet Sterne, Kessler, Goldstein & Fox P.L.L.C.
Apr
19
2012
Caraco v. Novo Nordisk (Prandin®): Federal Circuit Reversed in Patent Use Code Case Sterne, Kessler, Goldstein & Fox P.L.L.C.
Sep
6
2012
Akamai/McKesson Decided– Implications for Personalized Medicine Patents Sterne, Kessler, Goldstein & Fox P.L.L.C.
Jun
27
2014
FDA Draft Guidance - Best Practices for Developing Drug Trademarks - Food and Drug Administration Sterne, Kessler, Goldstein & Fox P.L.L.C.
Jan
30
2015
Practice Considerations Post Teva v. Sandoz Sterne, Kessler, Goldstein & Fox P.L.L.C.
Dec
11
2015
Florida Federal Court Rules that Apotex Must Give Amgen Notice Upon Biosimilar Licensure Sterne, Kessler, Goldstein & Fox P.L.L.C.
Aug
15
2017
Considerations for Developing a Global Patent Term Extension Strategy Sterne, Kessler, Goldstein & Fox P.L.L.C.
Aug
15
2014
FDA Releases Guidelines for 12- Year Period of Reference Product Exclusivity for Section 351(a) Biologics Sterne, Kessler, Goldstein & Fox P.L.L.C.
Sep
7
2012
Federal Circuit Reaffirms the Patentability of Isolated DNA in Association for Molecular Pathology v. Myriad Sterne, Kessler, Goldstein & Fox P.L.L.C.
Mar
12
2015
FDA Approves First US Biosimilar but Court Action Could Delay Market Entry Sterne, Kessler, Goldstein & Fox P.L.L.C.
May
1
2015
FDA Finalizes Guidance Documents on Biosimilarity Sterne, Kessler, Goldstein & Fox P.L.L.C.
Dec
3
2015
FDA Finalizes Guidance For Formal Meetings Between FDA and Biosimilars Applicants Sterne, Kessler, Goldstein & Fox P.L.L.C.
Oct
16
2017
Compulsory Licensing of Biopharmaceutical Inventions Sterne, Kessler, Goldstein & Fox P.L.L.C.
Mar
17
2014
USPTO Issues New Subject Matter Eligibility Examination Guidelines for Claims Involving Laws of Nature, Natural Principles, Natural Phenomena, and/or Natural Products Sterne, Kessler, Goldstein & Fox P.L.L.C.
Jun
4
2015
Act II: Oral Argument in Amgen v. Sandoz is heard at the Court of Appeals for the Federal Circuit Sterne, Kessler, Goldstein & Fox P.L.L.C.
Jul
27
2015
Kaneka v. Xiamen Kingdomway Group: Implicit Order Read into Method Steps of Industrial Biotechnology Patent Sterne, Kessler, Goldstein & Fox P.L.L.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins